It has been reported that ERα-positive breast cancers are often responsive to anti-estrogen therapy and generally have a better prognosis, while ERα-negative breast cancers are more aggressive and unresponsive to anti-estrogens [1]. Here, ESR1 is linked to breast carcinoma.